In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Kyverna Therapeutics, Inc., with a price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mitchell Kapoor has given his Buy rating due to a combination of factors including the attractive risk-reward profile of Kyverna Therapeutics, Inc. The company is poised to release five sets of data through 2026, which could demonstrate success across various pipeline programs. These upcoming catalysts, along with the company’s deeply negative enterprise value, make the stock an appealing investment opportunity.
Furthermore, Kyverna’s stock is trading at a significant discount to its cash reserves, providing a financial runway into 2027. This cash position allows investors to consider the stock as a call option with potential for meaningful upside if any of the forthcoming catalysts prove positive. The upcoming data release for myasthenia gravis (MG) in the fourth quarter of 2025 is seen as a high-impact catalyst, with early data showing promising results. This positions Kyverna’s KYV-101 as a potentially cost-effective cell therapy in the MG market, further supporting the Buy rating.
According to TipRanks, Kapoor is an analyst with an average return of -12.6% and a 38.08% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ionis Pharmaceuticals, and Summit Therapeutics.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $20.00 price target.